Top Markets
#1 Official Trump Official Trump +33.51%
#2 Siacoin Siacoin +20.98%
#3 Melania Meme Melania Meme +19.05%
#4 EXOD EXOD +18.93%
#5 Wrapped STX (Velar) Wrapped STX (Velar) +18.64%
#6 MowCat MowCat +18.17%
#7 POL (ex-MATIC) POL (ex-MATIC) +17.47%
#8 Wrapped POL Wrapped POL +16.96%
#9 Islamic Coin Islamic Coin +16.11%
#10 Siren Siren +15.86%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
GlycoNex Incorporation GlycoNex Incorporation

GlycoNex Incorporation

4168
Rank in Stocks #22943
GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in... GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.
Share Price
$0.71865803
Last synced: 2026-08-21
Market Cap
$80.86M
Change (1 day)
0.00%
Change (1 year)
-5.48%
Country
TW
Trade GlycoNex Incorporation (4168)

Category

Healthcare
P/E ratio for GlycoNex Incorporation (4168)
P/E ratio as of 2026 TTM: 0
According to GlycoNex Incorporation latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for GlycoNex Incorporation from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.